Incidence of apoptosis and cell proliferation in multiple myeloma: Correlation with bcl-2 protein expression and serum levels of interleukin-6 (IL-6) and soluble IL-6 receptor

European Journal of Haematology

Volumn 69, Issue 2, 2002, Pages 90-94

  Chaidos, Aristeidis I ^a   Bai, Maria C ^a   Kamina, Sevasti A ^a   Kanavaros, Panayiotis E ^b   Agnantis, Niki J ^a   Bourantas, Konstantinos L ^a,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b University of Thessaly School of Medicine   (Greece)

^c Department of Haematology ^*  (Greece)

Author keywords

Apoptosis; Bcl 2; Cell proliferation; Interleukin 6; Multiple myeloma

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; APOPTOSIS; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, INTERLEUKIN-6;

EID: 0036699033     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01634.x     Document Type: Article

References (27)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657.
2. Jelinek DF. Mechanisms of myeloma cell growth control. Hematol Oncol Clin North Am 1999;13:1145.
3. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863.
4. Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991;77:2688.
5. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997;89:227.
6. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994;84:3063.
7. Peters M, Muller A, Rose-John S. Interleukin-6 and Soluble Interleukin-6 Receptor. Direct Stimulation gp130 Hematopoiesis. Blood 1998;92:3495.
8. Gaillard JP, Liautard J, Klein B, Brochier J. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines. Eur J Immunol 1997;27:3332.
9. Gudo K. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997;3:614.
10. Hamilton MS, Barker HF, Ball J, Drew M, Abbot SD, Franklin IM. Normal and neoplastic human plasma cells express bcl-2 antigen. Leukemia 1991;5:768.
11. Tosi P, Pollacani A, Visani G, et al. In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. Eur J Haematol 1999;62:143.
12. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-KB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by Bcl-2. Blood 1999;93:3044.
13. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma, significance of plasmablastic subtype in morphological classification. Blood 1985;65:305-310.
14. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, JAEGER K, Sommerfeld W. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 1987;87:342-355.
15. Kanavaros P, Bai M, Stefanaki K, et al. Immunohistochemical expression of the p53, mdm2, 21/Waf-1. Rb, p16 Ki-67. Cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas. Histol Histopathol 2001;16:377-386.
16. Korkolopoulou P, Angelopoulou MK, Kontopidou F, et al. Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphomas: a multivariate survival analysis including Ki67 and p53 oncoprotein expression. Histopathology 1998;33:240.
17. Caligaris-Cappio F, Gottardi D, Alfarano A, et al. The nature of the B lymphocyte in B-chronic lymphocytic leukemia. Blood Cells 1993;19:601.
18. Czader M, Mazur J, Liliemark J, et al. Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived non-Hodgkin's lymphomas. Cancer 1996;77:1180.
19. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999;104:131.
20. Budke H, Orazi A, Neiman RS, Cattoretti G, John K, Barberis M. Assessment of cell proliferation in paraffin sections of normal bone marrow by the monoclonal antibodies Ki-67 and PCNA. Mod Pathol 1994;7:860-866.
21. Bai M, Agnantis NJ, Kamina SA, et al. Apoptotic and proliferative activity in benign and premalignant epithelial breast lesions detected by TUNEL and Ki-67 antibody. Breast Cancer Res 2001;3:276-283.
22. Evan G, Littlewood T. A matter of life and cell death. Science 1998;281:1317-1321.
23. Harada N, Hata H, Yoshida M, et al. Expression of Bcl-2 family of proteins in flesh myeloma cells. Leukemia 1998;12:1817.
24. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008.
25. Bataille R, Barlogie B, Yang Lu Z, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86:685.
26. Schaar CG, Kaiser U, Snijder S, et al. Serum interleukin-6 has no discriminatory role, in paraproteinaemia nor a prognostic role in multiple myeloma. Br J Haematol 1999;107:132.
27. Stasi R, Brunetti M, Parma A, Giulio D, Terzoli E, Pagano A. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 1998;82:1860-1866.